Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company whose news flow is closely tied to the development of ateganosine (THIO), a first-in-class telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). News about MAIA often centers on clinical milestones, regulatory designations, and financing activities that support its oncology programs.
Investors and observers following MAIA’s news can expect regular updates on its Phase 2 THIO-101 and Phase 3 THIO-104 trials. These items include announcements of first patient dosing, expansion into new countries, enrollment progress, and presentations of trial-in-progress posters at major conferences such as the Society for Immunotherapy of Cancer (SITC), the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and the European Society for Medical Oncology (ESMO) Congress.
MAIA’s press releases, many of which are furnished via Form 8-K filings, also highlight regulatory developments such as the U.S. FDA Fast Track designation for ateganosine in NSCLC and Orphan Drug Designations in additional tumor types. Another recurring theme in the company’s news is insider activity: open-market share purchases by the CEO and directors, and participation by board members in private placement financings, which the company frames as signals of confidence in the ateganosine platform.
On this news page, readers can review MAIA’s announcements related to clinical data signals, trial design details, international site activations, and capital raises that fund key study steps. For those tracking the progress of telomere-targeting approaches in oncology and the later-line NSCLC treatment landscape, MAIA’s news provides an ongoing record of how its investigational therapy is advancing through mid- to late-stage clinical development.
MAIA Biotechnology (NYSE American: MAIA) has announced positive updates from its Phase 2 THIO-101 trial, evaluating THIO sequenced with cemiplimab in advanced non-small cell lung cancer (NSCLC) patients who failed multiple standard therapies. Key highlights include:
1. Six patients have continued treatment for over 12 months, completing up to 21 cycles.
2. The THIO-cemiplimab combination shows significantly lower toxicity compared to standard treatments.
3. Treatment longevity suggests safety, efficacy, and ongoing benefits of MAIA's novel telomere-targeting therapy.
4. Current second-line NSCLC treatments typically last 3-4 months, while THIO patients are showing much longer treatment durations.
These results indicate THIO's potential as a durable and effective treatment for advanced NSCLC patients with options.
MAIA Biotechnology announced the FDA's approval of imetelstat, a telomerase inhibitor for treating myelodysplastic syndromes. This approval supports MAIA's approach to telomere-targeting therapies for cancer.
CEO Vlad Vitoc highlighted that telomere targeting is critical in treating specific cancers, noting their lead candidate, THIO, is in Phase 2 trials for high-risk non-small cell lung cancer (NSCLC). THIO has shown promising results in patients resistant to other treatments.
Telomerase, present in over 85% of human cancers, aids cancer cell proliferation. THIO disrupts telomere function, leading to rapid tumor cell death, underscoring the potential of telomere-targeting therapies.
MAIA Biotechnology announced significant milestones and clinical progress for their anticancer agent, THIO. Key achievements include more than $12 million in funding year-to-date, with $7.4 million raised in Q2'24. Recent Phase 2 clinical trial data demonstrated THIO's exceptional efficacy in treating non-small cell lung cancer (NSCLC), with a 38% overall response rate and a 5.5-month median progression-free survival, outperforming current treatments. The company secured a high-value clinical supply agreement for cemiplimab used in the trial. The median survival follow-up time reached 9.1 months. The cash position improved to $8.7 million as of March 31, 2024, bolstered by continued insider investment and strategic fundraising activities. MAIA's positive data at ASCO 2024 generated significant interest among oncologists.
MAIA Biotechnology announced new data from its Phase 2 THIO-101 clinical trial, showing promising results for the drug THIO when combined with cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC) patients who have failed 2 or more standard-of-care therapies.
The trial reports a favorable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85%, significantly surpassing the standard-of-care DCR of 25-35%. Median progression-free survival (PFS) for patients treated with THIO was 5.5 months, with a median survival follow-up time of 9.1 months.
Furthermore, 65% of patients crossed the 5.8-month overall survival (OS) threshold, and 85% crossed the 2.5-month PFS threshold. The data was presented at the ASCO 2024 Annual Meeting.
Full enrollment for the trial was completed ahead of schedule on February 19, 2024, and the company anticipates full efficacy data by the second half of the year. The treatment has been generally well tolerated by patients.
MAIA Biotechnology (NYSE American: MAIA), a clinical stage company specializing in telomere-targeting immunotherapies for cancer, will participate in the BIO International Convention from June 3-6, 2024, in San Diego. The event gathers over 20,000 biotech industry leaders globally. CEO Vlad Vitoc, M.D., will present findings from the Phase 2 THIO-101 clinical trial, which assesses the efficacy of THIO, a telomere-targeting agent, combined with the immune checkpoint inhibitor cemiplimab (Libtayo®) in treating advanced non-small cell lung cancer. This trial could mark the first completion of a telomere-targeting agent study in cancer treatment. Dr. Vitoc’s presentation is set for June 5 at 11:30 a.m. PDT in the San Diego Convention Center. The MAIA team will also hold meetings with key industry stakeholders during the event.
MAIA Biotechnology announced that an abstract from its Phase 2 THIO-101 clinical trial has been accepted for a poster presentation at the ASCO 2024 Annual Meeting. The trial involves the investigation of THIO, a telomere-targeting agent, sequenced with cemiplimab in treating advanced non-small cell lung cancer (NSCLC). The poster presentation is scheduled for June 3, 2024, from 1:30 pm to 4:30 pm CST in Chicago. MAIA emphasizes the uniqueness of THIO as the first cancer treatment of its kind in clinical development. Additional details will be accessible online on the ASCO website a week before the conference and on MAIA's website on the day of the presentation.
MAIA Biotechnology, Inc. announced that director Adelina Louie purchased 19,665 shares and warrants in a private placement of common stock, showing confidence in the company's mission of developing cancer immunotherapies. Louie, a top MAIA investor, has a background in finance and banking, with 30 years of experience at HSBC Group.
MAIA Biotechnology, Inc. announced that independent director Stan V. Smith, Ph.D., purchased 147,492 shares and warrants for 147,492 shares of MAIA's common stock as part of a recent private placement. MAIA entered into agreements for the purchase of 494,096 shares at $2.034 per share, raising approximately $1.0 million. The securities were issued pursuant to the Company's 2021 Equity Incentive Plan. Dr. Smith's purchase demonstrates support for MAIA's innovative cancer therapy approach.
Summary not available.
Summary not available.